Jonathan M. Ducore, M.D., M.P.H.

Education

M.D., Duke University School of Medicine, Durham NC 1973

M.P.H., UC Berkeley School of Public Health, Berkeley CA 2002

B.A., Rutgers University, New Brunswick NJ 1969

Internship: Pediatrics, University of Cincinnati Medical Center and Cincinnati Children's Hospital, Cincinnati OH 1973-1974

Residency

Pediatrics, University of Cincinnati Medical Center and Cincinnati Children's Hospital, Cincinnati OH 1974-1975

Fellowships

Molecular Oncology, Laboratory of Molecular Oncology, National Cancer Institute, National Institutes of Health, Bethesda MD 1978-1980

Pediatric Oncology, Pediatric Oncology Branch, National Cancer Institute, National Institutes of Health, Bethesda MD 1977-1978

Pediatric Hematology/Oncology, University of Colorado Medical Center and Denver Children's Hospital, Denver CO 1975-1977

Board Certifications

American Board of Pediatrics,

American Board of Pediatrics, Pediatric Hematology-Oncology,

California Medical License,

Professional Memberships

American Society of Hematology

Children�s Oncology Group

Hemostasis and Thrombosis Research Society

International Society on Thrombosis and Hemostasis

Thrombosis and Hemostasis Society of North America

World Federation on Haemophilia

Honors and Awards

Graduated Summa Cum Laude with Distinction in Zoology, 1969

Henry Rutgers Scholar, 1968, 1969

Elected, Phi Beta Kappa, 1968

Elected, Delta Phi Alpha, 1967

American Cancer Society Junior Faculty Clinical Fellowship Award, 1982, 1983, 1984, 1985

Select Recent Publications

Santagostino E, Lalezari S, Reding MT, Ducore J, Ng HJ, Poulsen LH, Michaels LA, Linardi CCG. afety and efficacy of BAY 94-9027, an extended-half-life factor VIII, during surgery in patients with severe hemophilia A: Results of the PROTECT VIII clinical trial. Thrombosis Research. 2019;183:13-19.

Thornburg CD, Ducore J. A novel approach to immune tolerance induction in haemophilia A with factor VIII inhibitor. Haemophilia. 2019 Jan;25(1):e48-e50. doi:10.1111/hae.13646. Epub 2018 Nov 23.

George LA, Sullivan SK, Giermasz A, Ducore J, Rasko J, Samelson-Jones BJ, Cuker A, Sullivan LM, Majumdar S, Teitel J, McGuinn CE, Ragni MV, Luk AY, Hui D, Wright JF, Chen Y, Wachtel K, Galvão AM, Winters A, Galas T, van der Loo J, Zelenaia O, Takefman D, Carr ME, Couto LB, Anguela XM, High KA. Endogenous prophylaxis for hemophilia B following gene therapy with a high specific activity Factor IX variant. New England Journal of Medicine. 2017;377(23):2215-27.

Ducore J, Lawrence J, Simpson M, Boggio L, Bellon A, Burggraaf J, Stevens J, Moerland M, Frieling J, Reijers J, Wang M. Safety and Dose-Dependency of Eptacog Beta (Activated) in a Dose Escalation Study of Non-Bleeding Congenital Hemophilia A or B Patients, With or Without Inhibitors. Haemophilia. 2017;23:844-51.

Liesner RJ, Abashidze M, Aleinkova O, Altisent C, Belletrutti MJ, Borel-Derlon A, Carcao M, Chambost, H, Chan, Dubey L, Ducore J, Fouzia NA, Gattens M, Gruel Y, GuilleL B, Kavardakova N, El Khorassani M, Klukowska A, Lambert T, Lohade S, Sigaud M, Turea V, Wu JKM, Vdovin V, Pavlova A, Jansen M, Belyanskaya L, Walter O, Knaub S, Neufeld EJ. Immunogenicity, Efficacy and Safety of Nuwiq® (Human-cl rhFVIII) in Previously Untreated Patients with Severe Haemophilia A – Interim Results from the NuProtect Study. Haemophilia. 2017;23:1-10.

Wang M, Lawrence JB, Quon DV, Ducore J, Simpson ML, Boggio LN, Mitchell IS, Yuan G, Alexander WA, Schved J-F. PERSEPT 1: a phase 3 trial of activated eptacog beta for on-demand treatment of hemophilia inhibitor-related bleeding. Haemophilia. 2017;23:832-43.

Buckner TW, Leavitt AD,Ragni,M, Kempton CL, Eyster E, Cuker A, Lentz SR, Ducore J, Leissinger C, Wang M,Key NS. Prospective, Multicenter Study of Postoperative Deep Vein Thrombosis in Patients with Haemophilia Undergoing Major Orthopedic Surgery. Thrombosis and Haemostasis. 2016;116(1):42-9.

Whitehead TP, Ward MH, Colt JS, Dahl G, Ducore J, Reiner K, Gunier RB, Hammond SK, Rappaport SM and Metayer C. Dust metal loadings and the risk of childhood lymphoblastic leukemia. Journal of Exposure Science and Environmental Epidemiology. 2015;25(6):593-8.

Ducore JM, Miguelino MG, Powell JS. Alprolix (recombinant Factor IX Fc fusion protein): extended half-life product for the prophylaxis and treatment of hemophilia B. Expert Rev Hematol. 2014;7(5):559-71.

Huang T, Ducore J. Children and adolescents with ALL are taller than expected at diagnosis. J Ped Hemat Onco. 2014;36(1):16-21.